Nanchang Weiyang Biochemical Pharmaceutical Co., Ltd.

Primary objective: To compare the differences in absorption extent and speed of levamlodipine besylate tablets (2.5 mg/tablet) produced by Jiangxi Renqi Pharmaceutical Co., Ltd. and amlodipine besylate tablets (5 mg/tablet, trade name: Norvasc®) certified by Pfizer Pharmaceuticals Co., Ltd. in healthy adults under fasting and postprandial administration conditions, and to evaluate their bioequivalence. Secondary objective: To evaluate the safety of levamlodipine besylate tablets (2.5 mg/tablet) produced by Jiangxi Renqi Pharmaceutical Co., Ltd. and amlodipine besylate tablets (5 mg/tablet, trade name: Norvasc®) certified by Pfizer Pharmaceuticals Co., Ltd. under fasting and postprandial administration conditions.

Primary objective: To compare the differences in the extent and rate of absorption of dapoxetine hydrochloride tablets (30 mg/tablet) provided by Jiangxi Renqi Pharmaceutical Co., Ltd. and dapoxetine hydrochloride tablets (30 mg/tablet, trade name: Priligy®) certified by Berlin-Chemie AG in healthy adults under fasting and postprandial administration conditions, and to evaluate their bioequivalence. Secondary objective: To evaluate the safety of dapoxetine hydrochloride tablets (30 mg/tablet) provided by Jiangxi Renqi Pharmaceutical Co., Ltd. under fasting and postprandial administration conditions.

The main purpose of the study was to use the Montelukast Sodium Granules (0.5g:4mg (in terms of Montelukast)) produced by Jiangxi Renqi Pharmaceutical Co., Ltd. as the test preparation (T), and the Montelukast Sodium Granules (0.5g:4mg (in terms of Montelukast), Singulair®) produced by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. as the reference preparation (R) for bioequivalence study according to the relevant provisions of bioequivalence study. Secondary purpose of the study was to observe the safety of the test preparation and the reference preparation Montelukast Sodium Granules in healthy subjects.